Palisade Bio (PALI) Other Non-Current Liabilities (2012 - 2026)
Palisade Bio (PALI) posted quarterly Other Non-Current Liabilities of $271000.0 for Q1 2026, up 13450.0% year-over-year from N/an in Q1 2025, and up 1.88% quarter-over-quarter from $266000.0 in Q4 2025.
Powered by 
Analysis
Palisade Bio (PALI) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Other Non-Current Liabilities for 15 consecutive years, with $271000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 13450.0% year-over-year to $271000.0; the TTM figure through Mar 2026 stood at $271000.0 (up 13450.0% YoY), while the FY2025 annual figure was $266000.0, up 77.33% from the prior year.
- Other Non-Current Liabilities climbed to $271000.0 in Q1 2026 per PALI's latest filing, from $266000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.7 million in Q1 2022 and bottomed at $2000.0 in Q2 2023.
- Historically, Other Non-Current Liabilities has averaged $223466.7 across 5 years, with a median of $75000.0 in 2025.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities slumped 99.57% — and 2026, when it soared 13450.0%.
- Palisade Bio's Other Non-Current Liabilities stood at $84000.0 in 2022, then plunged by 97.62% to $2000.0 in 2023, then soared by 7400.0% to $150000.0 in 2024, then jumped by 77.33% to $266000.0 in 2025, then gained by 1.88% to $271000.0 in 2026.
- Business Quant data shows PALI's Other Non-Current Liabilities at $271000.0 in Q1 2026, $266000.0 in Q4 2025, and $75000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 321,000.00 |
| Mar 31, 2026 | 333,000.00 |
| Dec 31, 2025 | 641,000.00 |
| Sep 30, 2025 | 283,000.00 |
| Jun 30, 2025 | 75,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | 152,000.00 |
| Sep 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 60,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | 212,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 18,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Sep 30, 2022 | 84,000.00 |
| Jun 30, 2022 | 469,000.00 |
| Mar 31, 2022 | 1.69 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 9.43 Mn |